EMA Withdrawn: Pelzont (laropiprant;nicotinic acid) — Merck Sharp Dohme Ltd

View source ↗

Summary

EMA announced the withdrawal of Pelzont (laropiprant and nicotinic acid) from the market for dyslipidemias.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias

Drugs mentioned

• Pelzont

Snippet

Status: Withdrawn. Therapeutic area: Dyslipidemias. MAH: Merck Sharp Dohme Ltd. Decision date: 10/04/2013